替諾福韋阿拉芬酰胺和恩替卡韋對乙型肝炎表面抗原水平下

StephenW

Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels

Kumada, Takashia; Toyoda, Hidenorib; Tada, Toshifumib; Yasuda, Satoshib; Miyake, Nozomib; Tanaka, JunkocAuthor Information
European Journal of Gastroenterology & Hepatology: February 2021 - Volume 32 - Issue 2 - p 255-260
doi: 10.1097/MEG.0000000000001733

    Buy

Abstract
Objective:

Tenofovir alafenamide is a new prodrug of tenofovir that allows for the treatment of patients with hepatitis B virus (HBV) at a lower dose than with tenofovir disoproxil fumarate, due to the more efficient delivery of tenofovir to hepatocytes. In this study, we compared entecavir and tenofovir alafenamide in terms of their ability to reduce hepatitis B surface antigen (HBsAg) in the same group of patients with HBV infection.
Methods:

During March and June 2018, 129 patients who received entecavir were switched to tenofovir alafenamide. Every 3– 6 months for 1 year before and after switching to tenofovir alafenamide, all patients underwent measurements of HBsAg, hepatitis core-related antigen (HBcrAg), calcium (Ca), inorganic phosphorus, and estimated glomerular filtration rate (eGFR).
Results:

The percent decline rate during the entecavir and tenofovir alafenamide phases at 6 months were 2.38% (−3.57 to 0.00) and −3.57% (−7.14 to 0.00), respectively, and those at 12 months were 3.03% (−6.57 to 0.00) and −5.56% (−7.41 to −2.50), respectively. HBsAg levels were reduced significantly more during the tenofovir alafenamide phase than during the entecavir phase (P < 0.0001). There were no significant differences in the percent declines of HBcrAg, Ca, inorganic phosphorus, or eGFR during the entecavir and tenofovir alafenamide phases after 1 year.
Conclusion:

tenofovir alafenamide significantly decreased HBsAg levels compared to entecavir.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

StephenW

替諾福韋阿拉芬酰胺和恩替卡韋對乙型肝炎表面抗原水平下降的影響比較

高田熊田;豐田章男（Hidenorib）；多田俊文;靖田（Satoshib）;三宅，Nozomib；田中市，Junkoc作者信息
歐洲胃腸病學和肝病學雜誌：2021年2月-第32卷-第2期-第255-260頁
doi：10.1097 / MEG.0000000000001733

    購買

抽象
目的：

替諾福韋alafenamide是替諾福韋的新藥，由於替諾福韋向肝細胞的遞送效率更高，因此它可以以比替諾福韋二富馬酸富馬酸酯更低的劑量治療乙型肝炎病毒（HBV）患者。在這項研究中，我們比較了恩替卡韋和替諾福韋阿拉芬酰胺在同一組HBV感染患者中減少乙型肝炎表面抗原（HBsAg）的能力。
方法：

在2018年3月和6月期間，將129名接受恩替卡韋的患者改用替諾福韋alafenamide。在轉用替諾福韋阿拉芬酰胺前後1年中，每3-6個月一次，對所有患者進行HBsAg，肝炎核心相關抗原（HBcrAg），鈣（Ca），無機磷和估計的腎小球濾過率（eGFR）測量。
結果：

恩替卡韋和替諾福韋阿拉芬酰胺階段在6個月期間的下降百分比分別為2.38％（-3.57至0.00）和-3.57％（-7.14至0.00），而在12個月時的下降百分比為3.03％（-6.57至0.00）和-5.56％（-7.41至-2.50）。在替諾福韋阿拉芬酰胺階段，HBsAg水平降低的幅度比恩替卡韋階段顯著降低（P <0.0001）。在1年後的恩替卡韋和替諾福韋阿拉芬酰胺階段，HBcrAg，Ca，無機磷或eGFR的下降百分比沒有顯著差異。
結論：

與恩替卡韋相比，替諾福韋阿拉芬酰胺可顯著降低HBsAg水平。
版權所有©2020 Wolters Kluwer Health，Inc.保留所有權利。